Certolizumab er opbygget, så det bindes til et af kroppens kemiske signalstoffer, der kaldes tumornekrosefaktor- alpha (TNF- alpha).
Certolizumab has been designed to bind to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha).